Day: September 21, 2022

Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomization Comparable survival benefits were also shown compared to ENCALS predicted median survival CNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedSALT LAKE CITY, Sept. 21, 2022 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension (OLE) at the 2022 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Clinical...

TomaGold Corporation TomaGold takes strategic position in the lithium sectorMONTREAL, Sept. 21, 2022 (GLOBE NEWSWIRE) — TOMAGOLD CORPORATION (TSXV: LOT) (OTCQB: TOGOF) (“TomaGold” or the “Corporation”) is pleased to announce the acquisition of a 100% interest in 38 claims from Noranda Royalties and the acquisition of 69 map-designated claims covering a total area of 5,487.52 ha (or 55 km2). These claims are located near Zones 1, 2, 3 and 6 of the James Bay Lithium Brisk project optioned by Monger Gold and along and south of the Trans-Taiga regional road and power line infrastructure, approximately 5 km from the LG-3 airport. These claims are also located on the same geological corridor as the Cancet (5.6% Li2O over 36.5 m) and Corvette (1.65% Li2O over 159.7 m) projects, held by Winsome Resources and Patriot Battery Metals...

Issuance of Anavex’s Newest U.S. Patent Will Expand Anavex’s Intellectual Property Portfolio Surrounding ANAVEX®2-73 NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,446,275 to Anavex, with claims to treatment methods using its leading drug candidate, ANAVEX®2-73 (blarcamesine) and its analogs, for ameliorating biochemical and functional abnormalities associated with methyl-CpG binding protein 2 defects...

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — ParcelPal Logistics Inc. (the “Company” or “ParcelPal”), (OTC:PTNYF) (CSE:PKG) (FSE:PT0A) is pleased to announce that it is endeavoring to retain a full time CFO given the Company’s recent expansion in the Western United States and with the growth and diversification of its customer base and operations. CEO Rich Wheeless stated, “Since I joined the Company in March 2020, we have grown our customer base and geographic operations. During this period, I have continued in the interim CFO position; however, we have determined that our growth and scope of operations now calls for the retention of added executive management strength in order to efficiently and effectively manage our Company in order to continue to grow and execute on additional milestones that we have laid...

Research Examines Regional Workforce Background Screening and Risk Management MEXICO CITY, Sept. 21, 2022 (GLOBE NEWSWIRE) — First Advantage – MultiLatin, a regional division of First Advantage Corporation (NASDAQ: FA), a leading global provider of HR technology solutions for screening, verifications, safety and compliance, today announced the availability of its Latin America (LATAM) 2022 Annual Trends Report. The report reveals illuminating regional perspectives on background screening trends throughout 2021 and the direct correlation to risk management.  According to the annual survey, 38 percent of respondents say they conduct background screens on job applicants to help minimize risk, followed by 27 percent to fill regulatory compliance, 17 percent to ensure applicants have the right qualifications for the role, and 6 percent...

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 9:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York City. A live webcast and archive of the event can be viewed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. About Axsome Therapeutics, Inc.Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions...

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. This approval makes PEDMARK the first and only treatment approved by the FDA in this area of significant unmet medical need. “The FDA approval of PEDMARK represents an important breakthrough for pediatric patients with localized,...

PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, being held September 21-24, 2022 in Nashville, TN and virtually. Poster Presentations:Abstract Title: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label Phase I/II study (ATB200-02) (Poster #104)Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.Date and Time: Thursday, September 22, 6:00-6:30 p.m. CT and Friday, September 23, 3:30-4:00 p.m. CTLocation: Ryman Exhibit Hall B1Abstract Title: Immunogenicity of cipaglucosidase alfa/miglustat...

Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD, first company employee WALTHAM, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today recognized a pioneering publication in the journal Cell. This article describes the research that serves both as foundational understanding of integrin conformation to broadly inform integrin drug development and also served as the catalyst for the formation of Morphic Therapeutic. The central biologic role of the integrin family of receptors has long been understood. The publication details the...

CALGARY, Alberta, Sept. 21, 2022 (GLOBE NEWSWIRE) — Crew Energy Inc. (TSX: CR; OTCQB: CWEGF) (“Crew” or the “Company“), a growth-oriented natural gas weighted producer operating in the world-class Montney play in northeast British Columbia (“NE BC”), is pleased to announce that we have achieved independent certification of our natural gas and natural gas liquids production from our NE BC Development area under the Equitable Origin EO100™ Standard for Responsible Energy Development (the “Certification”). The Certification confirms Crew’s best-practice methods for environmental, social and governance (“ESG”) performance in the energy sector and demonstrates our commitment to continuous improvement. As part of the Certification process, a team of approved third-party assessors from AECOM Canada Ltd. conducted...